Angioplasty Study Finds Much Room for Improvement

Armen Hareyan's picture
Advertisement

Angioplasty

Each year, more than 600,000 Americans have angioplasty procedures to open clogged arteries near their hearts, and treat or prevent a heart attack. But a new study shows that the quality and risk of their treatment can vary widely depending on where they go and demonstrates how it could be improved.

In a paper published in the journal Circulation, a group of Michigan researchers reports data from a multi-hospital project that studied angioplasty care and outcomes at five hospitals where doctors and nurses received guidance and data to help them improve angioplasty care, and seven hospitals where they did not.

The project is led by researchers from the University of Michigan Cardiovascular Center and was initially funded by the Blue Cross Blue Shield of Michigan Foundation, with ongoing funding from Blue Cross Blue Shield of Michigan and Blue Care Network. It's called the Blue Cross Blue Shield of Michigan Cardiovascular Consortium, or BMC2.

The results yielded a dramatic "before" and "after" contrast. Before the start of the project, the 3,731 patients treated at the five hospitals in one year received widely varying levels of care. Many never received drugs that could help prevent complications during or after their angioplasty, while others received far more than necessary of the blood-thinning drug heparin, or the dye that lets doctors see blockages while they perform the minimally invasive procedure.

Advertisement

There was also wide variation in how patients did afterward, including their risk of kidney damage related to the dye, and their need for emergency heart surgery and blood transfusions.

But five years later, after the intensive quality-improvement project was under way, the 5,901 patients treated at the same five hospitals in that year received much better and more uniform care, including much higher rates of preventive medication use, less use of heparin, and more appropriate amounts of dye. They also did better overall, with lower rates of complications related to their hearts and kidneys.

At the seven comparison hospitals, the researchers looked at data from 10,287 patients who had angioplasties during 2002, the same year as the "after" measurements at the five hospitals. They found wide variation in the use of preventive medications, heparin and dye, and higher rates of some complications than at the five other hospitals. All seven hospitals in the comparison group are now part of the quality-improvement project.

"The technology used in these procedures has reached such a point that patients' outcomes today depend more on practice variations than on limitations of technology," says Mauro Moscucci, M.D., the U-M cardiologist who leads the project with BCBSM's David Share, M.D., MPH. "It is crucial that we understand how individual physicians and hospitals vary, and work to reduce that variation so that each patient's care is delivered in a way that reduces risks and complications, and gives patients the best chance at a good outcome," he explains.

Adds Share, "The BMC2 project has provided physicians the resources they need to rigorously examine angioplasty practice, to better define optimal care, and to use what is learned to improve patient outcomes. It has been exceptionally gratifying to witness the high level of trust evidenced by otherwise competing physicians and hospitals as they work to raise the bar of quality for all patients

Share this content.

If you liked this article and think it may help your friends, consider sharing or tweeting it to your followers.
Advertisement